EBGLYSS

EBGLYSS™ (lebrikizumab-lbkz) is a biologic medication used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 years and over who weigh at least 40 kg. Here's a detailed overview of the medication:

1. **Mechanism of Action**: Ebglyss contains the active substance lebrikizumab, which is a monoclonal antibody that neutralizes interleukin 13 (IL-13), a protein that causes inflammation of the skin, leading to symptoms such as itching, redness, and dryness.
2. **Administration**: The medication is administered as an injection under the skin, usually in the thigh or belly, with a dosage frequency of every other week for up to 16 weeks. Patients who respond to treatment can then continue treatment with an injection every four weeks.
3. **Studies**: Ebglyss has been shown in studies to be more effective than a placebo in reducing the extent and severity of atopic dermatitis. It can be used in conjunction with other skin treatments such as topical corticosteroids or topical calcineurin inhibitors.
4. **Benefits**: Ebglyss provides relief from disease symptoms by preventing IL-13 from causing skin inflammation. It is particularly beneficial for patients whose eczema is not well controlled with topical prescription therapies or who cannot use those treatments due to adverse reactions.

In summary, Ebglyss is a targeted treatment for moderate-to-severe atopic dermatitis that works by neutralizing the protein responsible for skin inflammation, providing relief from symptoms and improving skin condition.